Cardiovascular comorbidity in COPD;Comorbilidad cardiovascular en la EPOC

Archivos de Bronconeumologia

Volumn 45, Issue SUPPL.5, 2009, Pages 18-23

  Cataluña, Juan José Soler ^a   García, Miguel Ángel Martínez ^a  

^a HOSPITAL GENERAL DE REQUENA   (Spain)

Author keywords

Cardiovascular disease; Chronic obstructive pulmonary disease; Comorbidity

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; STATIN; VASODILATOR AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPOXEMIA; MORBIDITY; MORTALITY; OXIDATIVE STRESS; PROGNOSIS; RISK FACTOR; SMOKING;

CARDIOVASCULAR DISEASES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 72049111510     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S0300-2896(09)72859-5     Document Type: Article

References (59)

1. Sin D.D., Wu L., and Man S.F. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic reviewe of the literature. Chest 127 (2005) 1952-1959
2. Sorile P.D., Kannel W.B., and O'Connor G. Mortality associated with respiratory function and symptoms in advance age. The Framingham Study. Am Rev Respir Dis 140 (1989) 379-384
3. Truelsen T., Prescott E., Lange P., Schnohr P., and Boysen G. Lung function and risk of fatal and non-fatal stroke. The Copenhagen City Heart Study. Int J Epidemiol 30 (2001) 145-151
4. Hole D.J., Watt G.C., Daved-Smith G., Hart C.L., Gillis C.R., and Harwthorne V.M. Impaired lung function and mortality risk in men and women: findings from the Refrew and Paisley prospective population study. BMJ 313 (1996) 711-715
5. Anthonisen N.R., Connett J.E., Enright P.L., and Manfreda J. Hospitalizations and mortality in Lung Health Study. Am J Respir Crit Care Med 166 (2002) 333-339
6. Engstrom G., Hedbland B., Janzon L., and Valind S. Respiratory decline in smokers and ex-smolkers-an independent risk factor for cardiovascular disease and death. J Cardiovasc Risk 7 (2000) 267-272
7. Hozawa A., Billings J.L., Shahar E., Ohira T., Rosamond W.E.D., and Folsom A.R. Lung function and ischemic stroke incidence: the Atherosclerosis Risk in Commnities Study. Chest 130 (2006) 1642-1649
8. Miravitlles M., Soriano J.B., Muñoz L., García-Rio F., Sánchez G., Sarmiento M., et al. COPD prevalence in Spain 2007 (EPI-SCAN study results). Eur Respir J Suppl 308s (2008)
9. Baeza Díez J.M., Del Val García J.L., Tomás Pelegrina J., Martínez Martínez J.L., Martín Peñacoba R., González Tejón I., et al. Epidemiología de las enfermedades cardiovasculares y factores de riesgo en atención primaria. Rev Esp Cardiol 58 (2005) 367-373
10. Soriano J.B., Visick G.T., Muellerova H., Payvandi N., and Hansell A.L. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 128 (2005) 2099-2107
11. Mapel D.W., Hurley J.S., Frost F.J., Petersen H.V., Picchi M.A., and Coultas D.B. Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. Arch Intern Med 160 (2000) 2653-2658
12. Johnston A.K., Mannino D.M., Hagan G.W., Davis K.J., and Kiri V.A. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. Thorax 63 (2008) 599-605
13. Sin D.D., and Man P.S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107 (2003) 1514-1519
14. Iwamoto H., Yokoyama A., Kitahara Y., Ishihawa N., Haruta Y., Yamene K., et al. Airflow limitation in smokers is associated with sublcinical atherosclerosis. Am J Respir Crit Care Med 179 (2009) 35-40
15. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
16. Woouters E.F. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2 (2005) 26-33
17. Koening W., Lowel H., Baumert J., and Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in the southern Germnay. Circulation 109 (2004) 1349-1353
18. Arroyo-Espliguero R., Avanzas P., Cosin-Sales J., Aldama G., Pizzi C., and Kaski J.C. C-reactive protein elevation and disease activity in patients with coronary heart disease. Eur Heart J 25 (2004) 401-408
19. Izquierdo Alonso J.L., and Arroyo-Espliguero R. EPOC y riesgo cardiovascular. Arch Bronconeumol 41 (2005) 410-412
20. Gan W.Q., Man S.F.P., Senthilselvan A., and Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systemic review and a metaanalysis. Thorax 59 (2004) 574-580
21. Bonomini F., Tengattini S., Fabiano A., Bianchi R., and Rezzani R. Atherosclerosis and oxidative stress. Histol Histopathol 23 (2008) 381-390
22. MacNee W., Maclay J., and McAllister D. Cardiovascular injury and repair in chronic obstructive pulmonary disease. Proc Am Thorac Soc 5 (2008) 824-833
23. Villar Álvarez F., De Miguel Diez J., and Álvarez-Sala J.L. EPOC y acontecimientos cardiovasculares. Arch Bronconeumol 44 (2008) 152-159
24. Zureik M., Benetos A., Neukirch C., Courbon D., Bean K., Thomas F., et al. Reduced pulmonary function is associated with central arterial stiffness in men. Am J Respir Crit Care Med 164 (2001) 2181-2185
25. Sabit R., Bolton C.E., Edwards P.H., Pettit R.J., Evans W.D., McEniery C.M., et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175 (2007) 1259-1265
26. Mills N.L., Miller J.J., Anand A., Robinson S.D., Frazer G.A., Anderson D., et al. Increased arterial stiffness in patients with chronic obstructive pulmomary disease: a mechanism for increased cardiovascular risk. Thorax 63 (2008) 306-311
27. Barr R.G., Mesia-Vela S., Austin J.H.M., Basner R.C., Keller B.M., Reeves A.P., et al. Impaired flow-mediated dilation is associated with low pulmonary function and emphysema in exsmokers: the Emphysema and Cancer Action Project (EMCAP) Study. Am J Respir Crit Care Med 176 (2007) 1200-1207
28. Kanazawa H., Asai K., Hirata K., and Yoshikawa J. Possible effects of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. Am J Med 114 (2003) 354-358
29. Eickhoff P., Valipour A., Kiss D., Schreder M., Cekici L., Geyer K., et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 178 (2008) 1211-1218
30. Chan S.R., and Blackburn E.H. Telomres and telomerase. Philos Trans R Soc Lond B Biol Sci 359 (2004) 109-121
31. Morla M., Busquets X., Pons J., Sauleda J., MacNee W., and Agusti A.G. Telomere shortening in smokers with and without COPD. Eur Respir J 27 (2006) 525-528
32. Tsuji T., Aoshiba K., and Nagai A. Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med 174 (2006) 886-893
33. Aviv H., Khan M.Y., Skurnick J., Okuda K., Kimura M., Garderne J., et al. Age dependent aneuploidy and telomere length of human vascular endothelium. Atherosclerosis 159 (2001) 281-287
34. Anthonisen N.R., Connett J.E., Kiley J.P., Altose M.D., Bailey W.C., Buist A.S., et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 272 (1994) 1497-1505
35. Tashkin D., Decramer M., Mannino D., Leimer I., and Kesten S. Elevated incidente of serious non-respiratory adverse event following COPD exacerbations in clinical trials. Am J Respir Crit Care 177 (2008) A132
36. Abroug F., Quanes-Besbes L., Nciri N., Sellami N., Addad F., Ben Hamda K., et al. Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disaase. Diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med 174 (2006) 990-996
37. Stolz D., Breidthardt T., Christ-Crain M., Bingisser R., Miedinger D., Leuppi J., et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbation of COPD. Chest 133 (2008) 1088-1094
38. Korff S., Katus H.A., and Giannitsis E. Differential diagnosis of elevated troponins. Heart 92 (2006) 987-993
39. Donaldson G.C., Hurst J.R., Smith C.J., Hubbard R.B., and Wedzicha J.A. Exacerbations and the risk of myocardial infarction in chronic obstructive pulmonary disease. Am J Respir Crit Care 177 (2008) A783
40. Berger J.S., Sanborn T.A., Sherman W., and Brown D.L. Effect of chronic obstructive pulmonary disease on survival of patients with coronary heart disease having percutaneous coronary intervention. Am J Cardiol 94 (2004) 649-651
41. Sin D.D., Anthonisen N.R., Soriano J.B., and Agustí A.G. Mortality in COPD: role of comorbidities. Eur Respir J 28 (2006) 1245-1257
42. Soriano J.B., and Izquierdo Alonso J.L. EPOC en la vida y en la muerte. Arch Bronconeumol 42 (2006) 421-422
43. McGarvey L.P., John M., Anderson J.E., Zvarich M., and Wise R. Ascertainment of causespecific mortality in COPD: operations of the TORCH clinical endpoint committee. Thorax 62 (2007) 411-415
44. Anthonisen N.R., Skeans M.A., Wise R.A., Manfreda J., Kanner R.E., Connett J.E., et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142 (2005) 233-239
45. Wedzicha J.A., Calverley P.M.A., Seemungl T.A., Hagan G., Ansari Z., Stockley A., et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177 (2008) 19-26
46. Antonelli-Incalzi R.A., Fuso L., De Rosa M., Rapiti E., Nardecchia B., and Pistelli R. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 10 (1997) 2794-2800
47. Gunen H., Hacievligyagil S.S., Kosar F., Mutlu L.C., Gulbas G., Pehlivan E., et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J 26 (2005) 234-241
48. Mancini G.J., Etminan M., Zhang B., Levesque L.E., FitzGerald M., and Brophy J.M. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptors blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 47 (2006) 2554-2560
49. Søyseth V., Brekke P.H., Smith P., and Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 29 (2007) 279-283
50. Alexeff S.E., Litonjua A.A., Sparrrow D., Vokonas P.S., and Schwart J. Statin use reduces decline in lung function: VA normative aging study. Am J Respir Crit Care Med 176 (2007) 742-747
51. Dransfield M.T., Rowe S.M., Johnson J.E., Bailey W.C., and Gerald L.B. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of copd. Thorax 63 (2008) 301-305
52. Van Gestel Y.R., Hoeks S.E., Sin D.D., Welten G.M., Schouten O., Witteveen H.J., et al. The impact of cardioselective b-blockers on mortality in patients with COPD and atherosclerosis. Am J Respir Crit Care Med 178 (2008) 695-700
53. Sin D.D., Lacy P., York E., and Man S.F. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170 (2004) 760-765
54. Huiart L., Ernst P., Panouil X., and Suissa S. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J 25 (2005) 634-639
55. Lofdahl C.G., Postma D.S., Pride N.B., Boe J., and Thoren A. Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur Respir J 29 (2007) 1115-1119
56. Sin D.D. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177 (2008) 1207-1214
57. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Mejoge S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. New Engl J Med 359 (2008) 1543-1554
58. Vassaux C., Torre-Bouscoulet L., Zeineldine S., Cortopassi F., Paz-Díaz H., Cellí B., et al. Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD. Eur Respir J 32 (2008) 1275-1282
59. Jörgensen K., Houltz E., Westfelt U., Nilson F., Scherstén H., and Ricksten S.E. Effects of lung volumen reduction surgery on left ventricular diastolic filling and dimensions in patients with severe emphysema. Chest 124 (2003) 1863-1870